| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating | 
|---|
																	
																	HC Wainwright & Co. analyst Ed Arce reiterates Albireo Pharma (NASDAQ:ALBO) with a Neutral and maintains $42 price target.
																	
																	
																	
																	Guggenheim analyst Seamus Fernandez downgrades Albireo Pharma (NASDAQ:ALBO) from Buy to Neutral.
																	
																	Cowen & Co. analyst Ritu Baral downgrades Albireo Pharma (NASDAQ:ALBO) from Outperform to Market Perform and lowers the ...
																	Jefferies analyst Eun Yang downgrades Albireo Pharma (NASDAQ:ALBO) from Buy to Hold and lowers the price target from $49 to ...